Cook Medical Announces the First Commercial Placement of the Zenith TX2(R) TAA Endovascular Graft in the United States
“The first placement of the TX2 in the United States showcases the advanced medical technologies Cook brings to the marketplace and marks a step forward in treating a broad range of TAA patients, safely and effectively, worldwide,” said Phil Nowell, global leader of Cook Medical’s Aortic Intervention business unit. “Dr. Lyden and others have told us they’ve been eagerly awaiting this device because it deploys with such accurate control and is actively fixed to the aorta, unlike competing devices. We believe this is a dramatic improvement for patients in a section of the aorta that really challenges endovascular devices for durability and that frequently offers only limited surgical repair options.
“With the highly skilled support of vascular surgeons like Dr. Lyden, we are now able to serve U.S. patients affected by TAAs (thoracic aortic aneurysms) or ulcers with the most minimally invasive alternatives available. Cook’s TX2 can be used on an additional subset of patients who may have been ineligible for treatment through open surgery, giving those affected by the disease, the opportunity to be treated with TEVAR,” Nowell added.
“The commercial release of the TX2 really made a huge difference for this patient,” said Dr. Lyden. “Using a small groin incision we were able to accomplish repair of his aneurysm in about 45 minutes. The two-piece device allowed customization to the patient’s anatomy to sit perfectly at the level of the left subclavian artery proximally and distally to near the celiac artery and prior repair. The hydrophilic Flexor delivery system passed through his anatomy to the treatment area with remarkable ease. This device will clearly make a huge impact on treating thoracic aortic disease.”
TAAs occur when a section of the aorta weakens and bulges outward like a balloon. The Cook Zenith TX2, a reinforced fabric tube that is sized to the length of the aorta is used to seal off the aneurysm, where it helps to relieve pressure on the aneurysm or ulcer and reduce the risk of rupture. The Zenith TX2 device is deployed from a catheter inserted through a small incision in the patient’s femoral artery. This procedure is far less invasive than traditional open surgery where physicians open the patient’s chest, clamp off and remove the diseased section of the aorta and replace it with a surgical graft. Post-operative and post-discharge recovery times are typically shorter with TEVAR, which may help patients return to their normal lifestyle routines far faster than for those who undergo open surgery.
About Cook Medical
Cook Medical was one of the first companies to help popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical procedures. Today, the company integrates device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Cook is a past winner of the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. For more information, visit www.cookmedical.com.
Contact:
Cook Medical Marsha Dawes, 812-339-2235, ext. 2750 Public Relations Account Associate marsha.dawes@cookmedical.com or Racepoint Group Jackie Hanley, 781-487-4625 jhanley@racepointgroup.com
Source: Cook Medical